Allurion Technologies, Inc. (ALUR)

Allurion Technologies' stock has experienced significant volatility over the past six months, with a substantial decline of 86.13% from November 19, 2024, to November 18, 2025. Key events impacting the stock include the third quarter 2025 earnings, which showed a 50% year-over-year revenue decline, a delayed 10-Q filing, and a price target decrease by analysts. The stock surged 10.9% in premarket trading after Allurion Technologies, Inc. announced passing critical FDA milestones. The company announced initial results on combining the Allurion Program with low-dose Tirzepatide, a new peer-reviewed publication demonstrating superior weight loss with the Allurion Smart Capsule, and a strategic distribution partnership with ProSurg Medical in Brazil. Q3 2024 revenue was negatively impacted by a product recall in France and a temporary suspension of the Allurion Balloon in the region.

While a tool exists to analyze demand seasonality for ALUR's stock, specific details regarding the seasonality of demand for Allurion Technologies' products and services were not explicitly provided in the search results. This suggests that while stock performance might exhibit seasonal trends, direct information on product demand seasonality is not readily available in the provided context.

Allurion Technologies, Inc. is a medical technology company focused on addressing obesity through its weight loss platform, operating in the Health Technology sector, specifically in Medical Specialties and Medical Devices. The company's primary offering is the Allurion Program, featuring the Allurion Gastric Balloon, a swallowable, procedure-less intragastric balloon for weight loss. The program is complemented by the Allurion Virtual Care Suite, a digital therapeutic that includes AI-powered remote patient monitoring tools.

Allurion Technologies, Inc. is headquartered in Natick, Massachusetts, USA, with an international presence in countries such as Spain, France, and Turkey. The company is expanding its global reach through strategic partnerships, including a distribution agreement with ProSurg Medical in Brazil, and a partnership with Minogue Medical Inc. for distribution channels in North America and Europe.

Allurion Technologies has experienced a mixed brand reputation over the past year, marked by both significant advancements and challenges. Positive aspects include clinical validation and innovation, regulatory progress with FDA approval for its Smart Capsule, strategic expansion through new distribution partnerships, and technological advancement with new patents. Reputation-affecting events include the temporary suspension of sales of the Allurion Balloon in France, macroeconomic headwinds, and a significant revenue decline and stock price drop.

Allurion Technologies Inc. has 27 institutional owners and shareholders, including Rtw Investments, Lp, UBS Group AG, and Vanguard Group Inc, holding a total of 2,817,551 shares. RTW Investments, Lp held 2,542,603 shares as of September 30, 2025. Leavitt Equity Partners III, L.P. is also noted as a major shareholder. Omar Ishrak, former Medtronic CEO and Chairman, is an equity investor in Allurion.